


1 Supplementary Fig. S1



2

3 **Figure S1** Identification of *CCDC65* engineered mice. (a) The diagram of the *CCDC65* engineered mice

4 construction strategy. (b) DNA agarose gel electrophoresis was used to detect the genotype of the


5 engineered mice. *CCDC65*^{+/+} (Red arrow), *CCDC65*^{+/-} (Blue arrow), and *CCDC65*^{-/-} (Green arrow). (c) The

6 mRNA expression of *CCDC65* in different genotypes and different age engineered mice. (d) *CCDC65* was

7 detected by western blot. *GAPDH* served as a loading control. (e) Immunohistochemical staining was


8 used in different genotype mice lung tissues.

9 Supplementary Fig. S2



10
 11 **Figure S2** CCDC65^{-/-} resulted in the disordered circulation of cerebrospinal fluid. (a) The percentage of
 12 sex and genotypes of mice (n=66). (b) The survival curves of CCDC65^{+/+}, CCDC65^{+/-}, and CCDC65^{-/-}
 13 mice(n=66). (c) and (d) The body shape and head shape of CCDC65^{+/+}, CCDC65^{+/-} and CCDC65^{-/-} mice.
 14 (e) The visceral shape of the CCDC65^{+/+} and CCDC65^{-/-} mice. (f) and (g) The CCDC65^{+/+} mice exhibited a
 15 larger head and smaller body compared with those of CCDC65^{+/+} or CCDC65^{+/-} mice. Models (f and g)
 16 were housed in different cages. (h) The image of enlarged brains of CCDC65^{+/+} and CCDC65^{-/-} mice. The
 17 brain of CCDC65^{-/-} mice were sunken and the brain of CCDC65^{+/+} or CCDC65^{+/-} was enlarged. (i) Images


18 of HE staining of paraffin-embedded whole-mount sagittal sections of brains demonstrated significant
19 expansion of lateral ventricle of *CCDC65*^{-/-} mice. Red arrow: lateral ventricle
20
21



23

24 **Figure S3** The efficiency identification of CCDC65 overexpression or knockdown. (a) CCDC65
 25 overexpression efficiency was detected by western blot. The flag tag resulted in the increased molecular
 26 weight of CCDC65. The lower band was the original protein and the upper band was the overexpression
 27 CCDC65. (b) GFP confirmed the success of lentivirus infection with lung adenocarcinoma cells. (c)
 28 CCDC65 knockdown efficiency was detected by western blot. (d-h) CCDC65 overexpression efficiency
 29 (corresponding to Figure 5a-i).

30




32


33 **Figure S4** CCDC65 mediated the ubiquitination degradation of ENO1. (a)(c) CHX chase analysis of
 34 ENO1 protein half-life in CCDC65 over-expressing and control group in H1975 and A549 cells. CHX
 35 (50µg/ml). (b)(d) The half-life curve of ENO1 protein in H1975 and A549 cells. (e) The effects of DMSO
 36 or MG132 (20µM) treatment on the stability of ENO1 protein in the control and CCDC65 overexpression
 37 groups. (f) Western blotting detected the effects of CCDC65 overexpression on the ubiquitination level
 38 of ENO1.

39

40 Supplementary Fig. S5




41
 42 **Figure S5** CCDC65 inhibited AKT1 phosphorylation. (a) The overexpression of CCDC65 inhibited the
 43 activation of AKT as well as its downstream such as p-mTOR(ser2448) and p-GSK3β(ser9), as well as
 44 promoted the expression of tumor suppressor genes such as p21 and p27. β-actin served as a loading
 45 control. (b) KEGG signaling pathways enrichment was based on the different mRNA expression genes
 46 between CCDC65+/+ and CCDC65+/- mice normal lung tissues.
 47



49

50 **Figure S6** The overexpression of c-Myc reversed the inhibition of cell proliferation and cell cycle
 51 induced by CCDC65 introduction. The effects of c-Myc on the growth of H1975 and A549 cells stably
 52 overexpressing CCDC65 were examined by the (f)CCK8, (g)EdU incorporation assays. Mean±SD (n=3). (h)
 53 Western blotting was used to detect the change of CCND1, c-Myc and ENO1 after the introduction of c-
 54 Myc in CCDC65 stably overexpressing cells.


55



57


58 **Figure S7** The overexpression of ENO1 reversed the inhibition of cell proliferation and cell cycle
 59 induced by CCDC65 introduction. The effects of ENO1 on the growth of H1975 and A549 cells stably
 60 overexpressing CCDC65 were examined by the (f)CCK8, (g)EdU incorporation assays. Mean±SD (n=3). (h)
 61 Western blotting was used to detect the change of c-Myc, CCND1, p-AKT1(ser473) and ENO1 after the
 62 introduction of ENO1 in CCDC65 stably overexpressing cells. “ns” means no statistical significance.

63



65
 66 **Figure S8** Inhibition of AKT1 phosphorylation reversed the cell proliferation and cell cycle induced
 67 by CCDC65 knockdown. MK-2206, an allosteric inhibitor of AKT, significantly inhibited the
 68 phosphorylation of AKT. CCDC65 knockdown cells were treated with DMSO, MK-2206 (5 μM, 10 μM),
 69 and then cell function was assessed by the (a) CCK8, (b, c) EdU incorporation assays. (e) Western blotting
 70 detected protein levels of c-Myc, CCND1, AKT1 and p-AKT1(ser473) in cells treated with DMSO, and MK-
 71 2206 (5 μM, 10 μM) respectively.

72



74
 75 **Figure S9** The expression correlation of CCDC65, ENO1 and c-Myc in TCGA database and CCDC65
 76 engineered mice induced lung adenocarcinoma/adenoma tissues. (a) mRNA expression correlation
 77 between CCDC65 and ENO1/c-Myc.(b) mRNA expression correlation between ENO1 and c-Myc. The
 78 data of mRNA expression of (a) and (b) were from the GDC TCGA LUAD database. (c) The expression
 79 of CCDC65, ENO1 and c-Myc was tested by immunohistochemical staining. (d) The grade of CCDC65,
 80 ENO1 and c-Myc in CCDC65+/+ and CCDC65+/- mice was based on the IHC score. (e) Correlation
 81 between CCDC65 and ENO1 expression. (f) Correlation between CCDC65 and c-Myc expression. (g)

82 Correlation between ENO1 and c-Myc expression.